Drug Type Small molecule drug |
Synonyms 18β-Glycyrrhetinic acid, Enoxolone (INN), Glycyrrhetic Acid + [7] |
Target |
Action inhibitors |
Mechanism 11β-HSD1 inhibitors(Corticosteroid 11-beta-dehydrogenase isozyme 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (19 Aug 1965), |
Regulation- |
Molecular FormulaC30H46O4 |
InChIKeyMPDGHEJMBKOTSU-YKLVYJNSSA-N |
CAS Registry471-53-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00156 | Glycyrrhetinic Acid |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Eczema | Japan | 19 Aug 1965 | |
| Neurodermatitis | Japan | 19 Aug 1965 | |
| Pruritus | Japan | 19 Aug 1965 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Obesity | Preclinical | China | 15 Nov 2025 | |
| Stomach Diseases | Preclinical | China | 01 Jul 2025 | |
| Hypertension, Pulmonary | Preclinical | China | 21 Feb 2025 | |
| Idiopathic Pulmonary Fibrosis | Preclinical | China | 01 Oct 2024 | |
| Psoriasis | Preclinical | China | 01 Jun 2024 | |
| Intestinal Diseases | Preclinical | China | 16 Apr 2024 | |
| MRSA - Methicillin resistant Staphylococcus aureus infection | Preclinical | United States | 19 Oct 2012 | |
| Neoplasms | Preclinical | United States | 15 Apr 2011 |
Phase 2 | 141 | (rs174535 (GG), Fish Oil Supplements) | aizspovqpi(jxiowncray) = gsqexxcpdi xaljcldnho (tzgluvttjg, 6.8) View more | - | 08 May 2018 | ||
Oleic Acid (rs174535 (GG), Placebo) | aizspovqpi(jxiowncray) = itpsvrhpmw xaljcldnho (tzgluvttjg, 7.6) View more | ||||||
Phase 2/3 | 15 | Glycyrrhinitic Acid (Glycyrrhinitic Acid) | ylpiiggyih(fxaorafjgu) = smpsqxqjlz jydvodglza (yepykfttfi, 0.26) | - | 28 May 2015 | ||
placebo (Placebo) | ylpiiggyih(fxaorafjgu) = towlzkibum jydvodglza (yepykfttfi, 0.20) |





